ArticleAntiviral research2010
Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model.
Article in Antiviral research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Neurovirulence of Usutu virus in human fetal organotypic brain slice cultures partially resembles Zika and West Nile virus.Scientific reports · 2024Article
- Review
- Bis(Benzofuran-1,3-International journal of molecular sciences · 2022Article
- AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster model.PLoS neglected tropical diseases · 2022Article
- Advance of structural modification of nucleosides scaffold.European journal of medicinal chemistry · 2021Review
- Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus.Antimicrobial agents and chemotherapy · 2019Article
- Development of a fluorescence-based method for the rapid determination of Zika virus polymerase activity and the screening of antiviral drugs.Scientific reports · 2019Article
- Viral RNA-Dependent RNA Polymerase Inhibitor 7-Deaza-2'-Antimicrobial agents and chemotherapy · 2019Article
- Syrian Hamster as an Animal Model for the Study on Infectious Diseases.Frontiers in immunology · 2019Review
- Review
- Structure and function of the Zika virus full-length NS5 protein.Nature communications · 2017Article
- Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors.The Journal of antimicrobial chemotherapy · 2017Article
- A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein.Journal of virology · 2016Article
- Nucleoside inhibitors of tick-borne encephalitis virus.Antimicrobial agents and chemotherapy · 2015Article
- Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus.Current opinion in virology · 2014Review
- BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.Antimicrobial agents and chemotherapy · 2014Article
- Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses.Antimicrobial agents and chemotherapy · 2014Article
- Antiviral strategies for hepatitis E virus.Antiviral research · 2014Review
- Experimental therapies for yellow fever.Antiviral research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Yellow fever virus (YFV) continues to cause outbreaks of disease in endemic areas where vaccine is underutilized. Due to the effectiveness of the vaccine, antiviral development solely for the treatment of YFV is not feasible, but antivirals that are effective in the treatment of related viral diseases may be characterized for potential use against YFV as a secondary indication disease. 2'-C-methylcytidine (2'-C-MeC), a compound active against hepatitis C virus, was found to have activity against the 17D vaccine strain of YFV in cell culture (EC(90)=0.32 microg/ml, SI=141). This compound was effective when added as late as 16 h after virus challenge of Vero cells. When administered to YFV-infected hamsters 4 h prior to virus challenge at a dose as low as 80 mg/kg/d, 2'-C-MeC was effective in significantly improving survival and other disease parameters (weight change, serum ALT, and liver virus titers). Disease was improved when compound was administered beginning as late as 3 d post-virus infection. Broadly active antiviral compounds, such as 2'-C-MeC, represent potential for the development of compounds active against related viruses for the treatment of YFV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.